Corilagin inhibits hepatocellular carcinoma cell proliferation by inducing G2/M phase arrest

Authors

  • Yanlin Ming,

    Corresponding author
    • The Research and Development Center for Medicinal Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian Province, China
    Search for more papers by this author
  • Zhizhong Zheng,

    1. The Research and Development Center for Medicinal Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian Province, China
    Search for more papers by this author
  • Lianghua Chen,

    1. The Research and Development Center for Medicinal Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian Province, China
    Search for more papers by this author
  • Guohua Zheng,

    1. The Research and Development Center for Medicinal Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian Province, China
    Search for more papers by this author
  • Shaosong Liu,

    1. The Research and Development Center for Medicinal Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian Province, China
    Search for more papers by this author
  • Yinhua Yu,

    1. Department of Gynecology, Obstetrics and Gynecology Hospital of Fudan University, Shanghai, China
    Search for more papers by this author
  • Qingxuan Tong

    1. The Research and Development Center for Medicinal Plants and Plant Drugs, Xiamen Overseas Chinese Subtropical Plant Introduction Garden, Xiamen, Fujian Province, China
    Search for more papers by this author

Corresponding author: e-mail: xmyanlin@gmail.com (Y. Ming); qingxuantong@yahoo.com.cn (Q. Tong)

Abstract

Hepatocellular carcinoma (HCC) is one of most common types of malignant tumours. Therefore, it is very important to identify powerful drugs and their antitumour mechanisms. Corilagin has a significant antitumour potential and lower toxicity in normal cells in vitro. The IC50 values of corilagin for normal Chang-liver cells and the HCC cell lines Bel7402 and SMMC7721 were 131.4, 24.5 and 23.4 µM, respectively, in the methyl thiazolyl tetrazolium (MTT) assay. MHCC97-H xenografts in Balb/c mice intraperitoneally injected with 30 mg/kg corilagin for 5 weeks showed a 47.3% inhibition of tumour growth in vivo. Furthermore, data from flow cytometry and Western blot analyses of cell cycle and cell cycle-related proteins suggest that corilagin arrests SMMC7721 cells at the G2/M phase by downregulating p-Akt and cyclin B1/cdc2 and upregulating p-p53 and p21Cip1. In conclusion, corilagin is a potential antitumour drug that is effective in retarding the growth of HCC, which is correlated with the activation of p-p53-p21Cip1-cdc2/cyclin B1.

Ancillary